VEGFA and Hypertension: Blockage of the VEGF pathway in cancer patients can cause adverse events such as hypertension, arterial thromboembolic events, cardiac dysfunction, proteinuria, renal toxicity, and compromised wound healing and tissue repair [9, 10].